NuCana plc (NCNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NuCana plc (NCNA) trades at $1.67 with AI Score 48/100 (Weak). NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments using its proprietary ProTide technology. Market cap: 11M, Sector: Healthcare.
Last analyzed: Mar 15, 2026NuCana plc (NCNA) Healthcare & Pipeline Overview
NuCana plc, based in Edinburgh, is a clinical-stage biopharmaceutical firm leveraging its ProTide technology to develop cancer treatments. Its pipeline features Acelarin, NUC-3373, and NUC-7738, targeting various cancers. The company operates in the competitive biotechnology sector, focusing on novel approaches to improve cancer therapy efficacy.
Investment Thesis
NuCana plc presents a high-risk, high-reward investment opportunity, driven by its ProTide technology and clinical pipeline. Key value drivers include the successful progression of Acelarin, NUC-3373, and NUC-7738 through clinical trials, with potential FDA approval and commercialization. The company's market capitalization is approximately $10 million as of March 15, 2026, reflecting the speculative nature of its pipeline. Catalysts include upcoming Phase III trial results for Acelarin in pancreatic cancer and Phase I/II data for NUC-7738. The investment thesis hinges on positive clinical data demonstrating improved efficacy and safety compared to existing treatments. Potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding, which could dilute existing shareholders. The company's beta of 1.71 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments using its proprietary ProTide technology.
- The company's lead product candidate, Acelarin, is in Phase III clinical trial for the treatment of patients with pancreatic cancer.
- NuCana is also developing NUC-3373, a ProTide transformation of 5-fluorouracil, currently in Phase I and Phase 1b/2 clinical trials for advanced solid tumors and colorectal cancer, respectively.
- NUC-7738, a novel nucleoside analog, is in Phase 1/2 clinical trials for advanced solid tumors and hematological tumors.
- The company has a market capitalization of $0.01 billion and a P/E ratio of -0.19 as of March 15, 2026.
Competitors & Peers
Strengths
- Proprietary ProTide technology platform.
- Diverse clinical pipeline targeting multiple cancer types.
- Research collaborations with leading universities.
- Potential to improve the efficacy and safety of existing chemotherapy agents.
Weaknesses
- Clinical-stage company with no approved products.
- High R&D costs and lengthy regulatory approval processes.
- Dependence on successful clinical trial outcomes.
- Limited financial resources and potential need for additional funding.
Catalysts
- Phase III trial results for Acelarin in pancreatic cancer (2027).
- Phase I/II data for NUC-7738 in advanced solid tumors and hematological tumors (2026).
- Potential for strategic partnerships and collaborations with pharmaceutical companies.
- Advancements in ProTide technology and expansion to new drug candidates.
Risks
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- Limited financial resources and potential need for additional funding.
- Currency risk due to being an ADR.
Growth Opportunities
- Growth opportunity 1: Successful completion and positive results from the Phase III clinical trial of Acelarin for pancreatic cancer could lead to FDA approval and commercialization, representing a significant revenue opportunity. The pancreatic cancer treatment market is projected to reach $4 billion by 2027. This timeline depends on trial outcomes and regulatory review, but approval could occur within the next 2-3 years. NuCana's ProTide technology could provide a more effective treatment option, giving it a competitive edge.
- Growth opportunity 2: Advancing NUC-3373 through clinical trials for advanced colorectal cancer offers another growth avenue. The colorectal cancer treatment market is expected to reach $18 billion by 2028. Positive Phase 1b/2 trial results could pave the way for further development and potential partnerships. This growth opportunity is contingent on demonstrating improved efficacy and safety compared to existing treatments, with potential commercialization in 3-5 years.
- Growth opportunity 3: Expanding the application of NUC-7738 to treat both solid tumors and hematological tumors broadens the potential patient base and market opportunity. The global hematological malignancies market is projected to reach $15 billion by 2027. Success in Phase 1/2 trials could lead to further development and potential FDA approval. This is a longer-term growth driver, with potential commercialization in 4-6 years, depending on clinical trial progress.
- Growth opportunity 4: Strategic partnerships and collaborations with other pharmaceutical companies could accelerate the development and commercialization of NuCana's product candidates. Collaborations can provide access to additional funding, expertise, and market reach. Identifying and securing such partnerships will be crucial for NuCana's long-term growth. The timeline for this is ongoing, as the company actively seeks collaboration opportunities.
- Growth opportunity 5: Expanding the application of ProTide technology to other cancer types beyond the current pipeline could unlock new growth opportunities. This involves identifying new drug candidates and initiating preclinical and clinical development. The potential market size depends on the specific cancer type targeted. This is a longer-term growth driver, with potential commercialization in 5-7 years, requiring significant R&D investment.
Opportunities
- Successful commercialization of Acelarin for pancreatic cancer.
- Expansion of NUC-3373 and NUC-7738 to treat other cancer types.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Application of ProTide technology to new drug candidates.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary ProTide technology platform.
- Clinical pipeline of novel cancer treatments.
- Research collaborations with leading universities.
About NCNA
NuCana plc, founded in 1997 and headquartered in Edinburgh, United Kingdom, is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through its innovative ProTide technology. This technology is designed to improve the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is undergoing Phase I, Ib, II, and III clinical trials for various cancers, including advanced solid tumors, recurrent ovarian cancer, biliary tract cancer, platinum-resistant ovarian cancer, and pancreatic cancer. NuCana is also developing NUC-3373, a ProTide transformation of 5-fluorouracil, currently in Phase I and Phase 1b/2 clinical trials for advanced solid tumors and colorectal cancer, respectively. Additionally, NUC-7738, a novel nucleoside analog, is in Phase 1/2 clinical trials for advanced solid tumors and hematological tumors. These clinical trials are crucial steps toward potential regulatory approval and commercialization. The company collaborates with Cardiff University and University College Cardiff Consultants Ltd. for ProTide design and evaluation and has an agreement with Cardiff ProTides Ltd. NuCana was formerly known as NuCana BioMed Limited before rebranding in August 2017. With a focus on addressing unmet needs in cancer therapy, NuCana aims to deliver more effective and tolerable treatments for patients.
What They Do
- Develops cancer treatments using ProTide technology.
- Conducts Phase I, Ib, II, and III clinical trials for Acelarin to treat various cancers.
- Develops NUC-3373, a ProTide transformation of 5-fluorouracil, for advanced solid tumors and colorectal cancer.
- Develops NUC-7738, a nucleoside analog, for advanced solid tumors and hematological tumors.
- Engages in research, collaboration, and license agreements for ProTide design and evaluation.
- Aims to improve the efficacy and safety of existing chemotherapy agents.
Business Model
- Develops proprietary cancer treatments based on ProTide technology.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties on sales of approved products.
Industry Context
NuCana plc operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The global oncology market is projected to reach $300 billion by 2028, driven by an aging population and increasing cancer incidence. NuCana's ProTide technology aims to improve the efficacy and safety of existing chemotherapy agents, differentiating it from competitors such as CASI Pharmaceuticals, Inc. (CASI), which focuses on developing and commercializing pharmaceutical products and CLSA Diagnostics (CLSD) which is a diagnostics company.
Key Customers
- Cancer patients in need of more effective treatments.
- Oncologists and healthcare providers who prescribe cancer therapies.
- Pharmaceutical companies seeking to expand their oncology portfolios.
Financials
Chart & Info
NuCana plc (NCNA) stock price: $1.67 (+0.01, +0.30%)
Latest News
-
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
MT Newswires · Mar 25, 2026
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Mar 20, 2026
-
Unusual Machines, NuCana, Navigator Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga · Mar 20, 2026
-
NuCana Q4 2025 EPS $0.00 and Revenue $0.00
benzinga · Mar 19, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NCNA.
Price Targets
Wall Street price target analysis for NCNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates NCNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
12 Health Care Stocks Moving In Friday's Pre-Market Session
Unusual Machines, NuCana, Navigator Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NuCana Q4 2025 EPS $0.00 and Revenue $0.00
Leadership: Hugh Stephen Griffith
CEO
Hugh Stephen Griffith serves as the Chief Executive Officer of NuCana plc. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology drug development and commercialization. He has held leadership positions in various pharmaceutical companies, overseeing clinical trials, regulatory submissions, and market access strategies. Griffith's expertise spans drug discovery, preclinical research, and clinical development.
Track Record: Under Hugh Stephen Griffith's leadership, NuCana plc has advanced its clinical pipeline, including Acelarin, NUC-3373, and NUC-7738, through various phases of clinical trials. He has overseen strategic collaborations and partnerships to support the company's research and development efforts. Key milestones include the initiation of Phase III trials for Acelarin in pancreatic cancer and the advancement of NUC-3373 and NUC-7738 into Phase I/II trials.
NuCana plc ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For NuCana plc (NCNA), each ADR represents a specific number of ordinary shares of NuCana plc traded on its home market. This allows U.S. investors to easily invest in NCNA without dealing with foreign exchanges.
- Home Market Ticker: Edinburgh, GB
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About NCNA (Healthcare)
What does NuCana plc do?
NuCana plc is a clinical-stage biopharmaceutical company that focuses on developing cancer treatments using its proprietary ProTide technology. This technology aims to improve the efficacy and safety of existing chemotherapy agents. The company's pipeline includes Acelarin, NUC-3373, and NUC-7738, each in various phases of clinical trials for different cancer types. NuCana seeks to address unmet needs in cancer therapy by delivering more effective and tolerable treatments for patients, potentially through partnerships and out-licensing.
What do analysts say about NCNA stock?
Analyst coverage of NuCana plc is limited, reflecting its small market capitalization and clinical-stage nature. Consensus estimates are not widely available. Key valuation metrics are difficult to assess due to the company's lack of revenue and profitability. Growth considerations hinge on the successful progression of its clinical pipeline and potential FDA approval of its product candidates. Investors should carefully evaluate the risks and uncertainties associated with investing in a clinical-stage biopharmaceutical company.
What are the main risks for NCNA?
The main risks for NuCana plc include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. The company's financial resources are limited, and it may need to raise additional funding, which could dilute existing shareholders. Patent expiration and generic competition also pose a threat. As an ADR, NCNA is subject to currency risk. The success of the company depends on the successful development and commercialization of its product candidates.
How does NuCana plc manage patent expiration risks?
NuCana plc manages patent expiration risks through a multi-faceted approach. This includes actively seeking patent protection for its ProTide technology and drug candidates, as well as pursuing patent extensions and new patent filings to prolong exclusivity. The company also focuses on developing new formulations and delivery methods to create additional intellectual property. Furthermore, NuCana monitors the competitive landscape and anticipates potential biosimilar competition to proactively mitigate risks.
What are the key growth opportunities for NCNA in healthcare?
NuCana plc's key growth opportunities in healthcare lie in expanding its pipeline of cancer treatments and leveraging its ProTide technology to develop new drug candidates. The company can also explore strategic partnerships and collaborations to accelerate the development and commercialization of its products. Geographic expansion into new markets and diversification into other therapeutic areas represent additional growth avenues. Successful clinical trial outcomes and regulatory approvals are crucial for realizing these growth opportunities.
What are the key factors to evaluate for NCNA?
NuCana plc (NCNA) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary ProTide technology platform. Primary risk to monitor: Clinical trial failures and regulatory setbacks. This is not financial advice.
How frequently does NCNA data refresh on this page?
NCNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NCNA's recent stock price performance?
Recent price movement in NuCana plc (NCNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary ProTide technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Analyst coverage may be limited.